ClinicalTrials.Veeva

Menu

Dysfunctional Adiposity and Glucose Impairment (DICAMANO)

U

University of Navarra

Status

Completed

Conditions

Carbohydrate Intolerance
Visceral Obesity
Oral Glucose Tolerance Test
Obesity, Abdominal
Insulin Resistance
Cardiovascular Risk Factor
Beta-cell Function
Body Composition

Study type

Observational

Funder types

Other

Identifiers

NCT03506581
167/2016

Details and patient eligibility

About

This is a large and comprehensively phenotyped cohort with fasting glycaemia where the predictive value of body composition and anthropometric measures of total and central fat distribution for postprandial carbohydrate intolerance are studied.

Full description

Subjects aged 18-70 years, who attended the Department of Endocrinology and Nutrition of the Clínica Universidad de Navarra from 2009-2014 for a check-up were offered to participate in the DICAMANO study. 853 subjects agreed to take part. Only those individuals with a normal fasting glucose level (≤5.5 mmol l-1) were analysed. Subjects with T2DM or severe renal, liver or thyroid dysfunction were excluded. Participants were instructed to temporarily discontinue for 48 hours any medication known to affect glucose or lipid metabolism. On the day of the study visit, each subject had a complete routine clinical assessment to evaluate the presence of cardiovascular, respiratory, renal or endocrine disorders. All patients underwent a 75-g OGTT with a concomitant anthropometric study, blood pressure monitoring and lipid profile analyses. They were classified by glucose tolerance on the basis of blood glucose levels according to ADA diagnostic criteria for T2DM (2017). Carbohydrate intolerance was defined as a 2-hOGTT glucose level ≥7.8 mmol l-1 (mg dl-1). Body composition, visceral adipose tissue, anthropometry study, OGTT-based parameters and cardiovascular risk factors are measured.

Enrollment

853 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Fasting glucose level ≤ 5.5 mmol l-1
  • BMI ≥ 25

Exclusion criteria

  • Type 2 diabetes mellitus
  • Severe renal, liver or thyroid dysfunction

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems